- Home
- LPSN vs ALXO Comparison
LPSN vs ALXO Comparison
Compare LPSN & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPSN
- ALXO
- Stock Information
- Founded
- LPSN 1995
- ALXO 2015
- Country
- LPSN United States
- ALXO United States
- Employees
- LPSN N/A
- ALXO N/A
- Industry
- LPSN EDP Services
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- LPSN Technology
- ALXO Health Care
- Exchange
- LPSN Nasdaq
- ALXO Nasdaq
- Market Cap
- LPSN 84.5M
- ALXO 93.7M
- IPO Year
- LPSN 2000
- ALXO 2020
- Fundamental
- Price
- LPSN $6.31
- ALXO $1.54
- Analyst Decision
- LPSN Hold
- ALXO Strong Buy
- Analyst Count
- LPSN 1
- ALXO 6
- Target Price
- LPSN N/A
- ALXO $3.30
- AVG Volume (30 Days)
- LPSN 410.9K
- ALXO 441.2K
- Earning Date
- LPSN 11-10-2025
- ALXO 11-07-2025
- Dividend Yield
- LPSN N/A
- ALXO N/A
- EPS Growth
- LPSN N/A
- ALXO N/A
- EPS
- LPSN N/A
- ALXO N/A
- Revenue
- LPSN $271,750,000.00
- ALXO N/A
- Revenue This Year
- LPSN N/A
- ALXO N/A
- Revenue Next Year
- LPSN N/A
- ALXO N/A
- P/E Ratio
- LPSN N/A
- ALXO N/A
- Revenue Growth
- LPSN N/A
- ALXO N/A
- 52 Week Low
- LPSN $5.44
- ALXO $0.40
- 52 Week High
- LPSN $31.20
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- LPSN 71.16
- ALXO 47.09
- Support Level
- LPSN $5.81
- ALXO $1.51
- Resistance Level
- LPSN $7.16
- ALXO $1.90
- Average True Range (ATR)
- LPSN 0.60
- ALXO 0.13
- MACD
- LPSN -0.03
- ALXO -0.04
- Stochastic Oscillator
- LPSN 50.73
- ALXO 12.20
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.